The CRC Molecular Landscape: Why Most Patients Still Lack Effective Options

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, and the fourth and third leading cause of cancer mortality in males and females respectively — figures cited consistently across multiple Genentech patent filings. That epidemiological weight sits alongside a striking therapeutic gap: the disease’s molecular heterogeneity means that the treatments proven to work for one subpopulation are actively contraindicated in another.

The central fault line runs between microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) CRC — which respond to checkpoint inhibitors — and the much larger population of microsatellite-stable (MSS) or proficient mismatch repair (pMMR) CRC, which is largely refractory to current immunotherapies. Retrieved patent filings and academic literature retrieved across targeted searches consistently identify this MSS/pMMR majority as the primary unmet need in the field.

Three molecular targets define the current competitive landscape. KRAS mutations — particularly G12C and G12D — are present in over 40% of CRC cases and constitute the primary exclusion criterion for anti-EGFR therapy. EGFR itself, targeted by cetuximab and panitumumab, is only actionable in KRAS wild-type patients, a population where a randomised phase II trial (WJOG 6210G, n=117 eligible patients) reported median overall survival of 16.2 months with panitumumab plus FOLFIRI versus 13.4 months with bevacizumab plus FOLFIRI. And the VEGF/VEGFA axis — addressed by bevacizumab — is increasingly being repositioned not as a standalone strategy but as a combination partner for immune checkpoint and innate immune agents.

PD-1/PD-L1 Checkpoint Inhibition: From MSI-H Niche to MSS Ambition

PD-1 and PD-L1 axis blockade is one of the most prominent therapeutic themes across the retrieved patent dataset, with key agents including pembrolizumab, nivolumab, atezolizumab, and cemiplimab referenced across filings from TESARO, Novartis, Janssen Biotech, Genentech, and Regeneron. The biomarker story is well-established: multiple patents specifically address dMMR/MSI-H CRC as the subpopulation where checkpoint inhibition works, and Janssen Biotech’s pending Chinese patent explicitly claims an objective response rate of ≥35% in this subgroup with an anti-PD-1 antibody.

The academic evidence base reinforces this picture. A multi-institutional Italian group analysed immune exhaustion gene expression in 594 CRC tumours from the TCGA PanCancer cohort, identifying PD-L1, LAG3, and T-bet as co-associated with MSI/dMMR tumours and shorter overall survival, with a Cramér’s V correlation of 0.3 with MSI/dMMR subtype. This transcriptomic rationale directly supports the emerging strategy of combined checkpoint blockade in the MSI-H population — and, more ambitiously, in MSS CRC.

“The challenge of MSS CRC — comprising the majority of advanced CRC — lacking checkpoint inhibitor sensitivity is a recurring theme across every major patent filing in this dataset.”

The patent activity signals that the field is moving beyond PD-1 monotherapy in two directions simultaneously. First, towards dual checkpoint blockade: Bristol-Myers Squibb’s 2024 CRC-specific patent on relatlimab (anti-LAG-3) plus nivolumab (anti-PD-1) explicitly covers both MSS and MSI-H CRC across all lines of therapy, signalling an ambition to extend beyond the MSI-H niche. Second, towards biomarker-driven patient selection in non-standard populations: Gil Medical Center’s 2023 US pending patent describes a linear discriminant model classifying obese CRC patients by gene mutation type and immune signature to identify immunotherapy candidates — a direction with no clear parallel elsewhere in the dataset.

KRAS Inhibition Grows Up: From Undruggable to Combination Target

KRAS has moved from a target once considered undruggable to an active combination anchor in the CRC pipeline. Retrieved results reveal a dedicated cluster of KRAS-targeted combination strategies specifically addressing KRAS G12C and G12D mutant cancers — mutations present in over 40% of CRC cases, per Gilead Sciences filings, and the primary reason these patients cannot benefit from anti-EGFR antibodies such as cetuximab.

The most clinically grounded signal comes from Foundation Medicine’s 2023 WO patent on liquid biopsy-detected kinase fusions, which references adagrasib — a KRAS G12C inhibitor — as a standard prior-treatment agent in CRC samples analysed for acquired resistance mutations. This positions adagrasib in active clinical use context, and the patent’s identification of secondary EGFR mutations (V441G, G465R) and KRAS Q61H as acquired resistance mechanisms signals that the field is already moving into next-generation KRAS inhibitor design. According to FDA regulatory filings, adagrasib received accelerated approval for KRAS G12C-mutated CRC, reflecting the clinical maturity of this target class.

On the combination front, two distinct strategies are emerging from the patent record. I-Mab Biopharma’s 2024 Brazilian patent describes co-administration of a KRAS inhibitor with a CD47/SIRPα blocking agent to stimulate macrophage phagocytosis of KRAS-mutant cancer cells — harnessing innate immunity to compensate for the adaptive immune resistance of MSS tumours. A separate filing from Liu Bo (WO, 2022) covers combinations of a KRAS G12C inhibitor with a SHP2 inhibitor and/or a PD-1 inhibitor, addressing both upstream pathway reactivation and adaptive immune suppression simultaneously.

Within KRAS wild-type CRC, the Merck Patent GmbH portfolio — active across EP, IL, ES, SG, AU, CA, and CN — continues to refine the biomarker story for cetuximab efficacy. Beyond KRAS status at codons 12 and 13, the filings document that even within the KRAS wild-type population, approximately 40% of patients do not respond to cetuximab, motivating further biomarker discovery including EREG (epiregulin) and AREG (amphiregulin) expression as predictors of anti-EGFR benefit. Research published through ASCO has consistently highlighted the clinical relevance of these secondary biomarkers in refining patient selection for EGFR-targeted therapy.

Genentech’s MEK + PD-1 + VEGF Triple Combination: The Broadest IP Claim in the Field

The most consistently filed combination strategy in the retrieved dataset is Genentech’s patent family covering a three-agent combination of a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor specifically for CRC and metastatic CRC. At least five retrieved filings span WO, CA, AU, MX, and IL jurisdictions, all with consistent priority dating to August 2016 — meaning this IP has been under active prosecution for nearly a decade.

The mechanistic rationale is distinctive and directly addresses the MSS CRC problem. MEK inhibition targets the KRAS downstream MAPK pathway, which may enhance immune susceptibility of tumour cells — in effect, making immunologically “cold” MSS tumours more visible to the immune system. VEGF inhibition simultaneously normalises the tumour vasculature and the immunosuppressive microenvironment, together potentiating checkpoint immunotherapy. This three-pronged approach — pathway suppression, vascular normalisation, and immune checkpoint release — represents the most elaborated mechanistic logic for converting MSS CRC into an immune-responsive tumour in the retrieved dataset.

No phase III CRC-specific clinical trial outcomes for this triple combination are detectable in the retrieved dataset. However, the breadth of jurisdiction filings and the sustained prosecution timeline suggest this remains an active programme. VEGF pathway inhibition is also addressed in USC’s multi-jurisdictional patent portfolio, which covers genomic polymorphisms in VEGF and VEGFR2 (KDR) as predictive biomarkers for anti-angiogenic therapy response in CRC — providing a potential companion diagnostic layer for VEGF-containing combinations. According to data from ClinicalTrials.gov, MEK inhibitor combinations with immunotherapy agents are being explored across multiple oncology indications, providing broader context for Genentech’s CRC-specific strategy.

LAG-3, CD47/SIRPα, and the Next Wave of Combination Immunotherapy

Beyond the established PD-1 axis, two emerging checkpoint strategies are generating significant patent activity in CRC: LAG-3 dual blockade and CD47/SIRPα innate immune checkpoint inhibition. Both are explicitly designed to address patient populations — MSS CRC and KRAS-mutant CRC — that current single-agent immunotherapy cannot reach.

LAG-3 + PD-1: Dual Checkpoint for Both MSS and MSI-H CRC

Bristol-Myers Squibb holds a pending Chinese patent filed in October 2024 specifically covering treatment of colorectal cancer — including unresectable, advanced, metastatic, MSS, and MSI-H subtypes — with relatlimab (anti-LAG-3, 480 mg) combined with nivolumab (anti-PD-1, 480 mg). The patent addresses CRC across all treatment lines, including patients who have progressed after fluoropyrimidines, oxaliplatin, irinotecan, anti-VEGF, anti-EGFR, and regorafenib. This is a heavily pre-treated population with extremely limited options, and the explicit inclusion of MSS CRC is the most ambitious claim in the checkpoint blockade section of this dataset. The patent’s specification of dosing regimens (480 mg per antibody) suggests a clinical-stage or near-clinical-stage programme.

TESARO (now part of GSK) holds a complementary Singapore patent on anti-LAG-3 antibodies, and the TCGA-based Italian study of 594 CRC tumours provides the transcriptomic underpinning: LAG3 is co-expressed with PD-L1 as an immune exhaustion gene, particularly in MSI/dMMR tumours, supporting the biological rationale for dual blockade. The LAG-3 landscape in oncology is being closely tracked by organisations such as ESMO, which has published guidance on emerging checkpoint targets relevant to CRC.

CD47/SIRPα: Harnessing Innate Immunity Against KRAS-Mutant Tumours

The CD47/SIRPα axis — the “don’t eat me” signal that tumour cells exploit to evade macrophage phagocytosis — is addressed in Gilead Sciences’ WO, CA, and AU filings (2023–2024) and in I-Mab Biopharma’s 2024 Brazilian patent. Gilead’s filings describe magrolimab (anti-CD47) combined with bevacizumab (anti-VEGFA) plus optional FOLFIRI chemotherapy, explicitly targeting KRAS-mutant metastatic CRC patients who cannot benefit from anti-EGFR therapies. The combination logic is that blocking CD47 re-enables macrophage-mediated phagocytosis of tumour cells, while bevacizumab normalises the tumour vasculature. I-Mab extends this further by co-administering a KRAS G12C or G12D inhibitor alongside the CD47 blocking agent, creating a synthetic strategy that targets both the oncogenic driver and the innate immune evasion mechanism simultaneously.

Strategic Implications for Drug Developers and IP Teams

The CRC drug pipeline, as reflected in the retrieved patent and literature dataset, is converging on three strategic imperatives: addressing KRAS-mutant MSS CRC, broadening checkpoint immunotherapy beyond the MSI-H niche, and characterising acquired resistance before it becomes a clinical problem. Each imperative carries specific IP and competitive intelligence implications.

KRAS-mutant mCRC is the highest-value white space. Over 40% of CRC cases are KRAS-mutant and ineligible for anti-EGFR therapy. The retrieved signals indicate that CD47/SIRPα plus KRAS inhibitor combinations (I-Mab, Gilead) and MEK plus immune checkpoint combinations (Genentech) are the primary IP vectors competing to address this population. For drug developers, this is both an opportunity — the unmet need is acute and the patient population is large — and a freedom-to-operate risk, given Genentech’s broad multi-jurisdiction claims dating to 2016.

Dual and multi-checkpoint blockade is becoming the competitive baseline. The emergence of LAG-3 plus PD-1 (Bristol-Myers Squibb), PD-1 plus TIM-3, and STING agonist plus PD-1 combinations — signalled across BMS, TESARO, and Novartis filings — suggests that PD-1 monotherapy will increasingly be challenged by combination immunotherapy regimens in MSI-H CRC, and by novel combinations targeting MSS CRC. Developers entering the checkpoint space in CRC should assume a combination-therapy competitive environment.

Liquid biopsy-guided resistance characterisation is maturing rapidly. Foundation Medicine’s 2023 WO patent on kinase fusions and acquired resistance mutations (EGFR V441G/G465R, KRAS Q61H) post-adagrasib treatment signals that the KRAS G12C inhibitor resistance landscape is already being systematically mapped. This is likely to foreshadow next-generation KRAS inhibitor or combination designs, and may create IP opportunities in resistance-specific therapeutic strategies. The WIPO patent database reflects a global surge in liquid biopsy-related filings across oncology, consistent with the CRC-specific signals identified here.

“The emergence of dual and multi-checkpoint blockade — LAG-3 + PD-1, PD-1 + TIM-3, STING agonists + PD-1 — suggests that PD-1 monotherapy will increasingly be challenged by combination immunotherapy regimens in both MSI-H and MSS CRC.”

CDK4/6 inhibition is entering the CRC combination space from an unexpected angle. G1 Therapeutics’ 2022 WO patent on transient CDK4/6 inhibition within FOLFOXIRI/FOLFIRINOX-based chemotherapy for pMMR/MSS mCRC is not a direct antitumour CDK4/6 strategy — it is a cytoprotection strategy designed to reduce chemotherapy-induced myelosuppression, enabling more intensive dosing. Edigene Therapeutics’ biomarker-driven CDK4/6 and CDK7 inhibitor patents (CDK6, CCND2, MYC, SMAD4 as relevant biomarker genes) represent a complementary precision oncology approach from a China-based biotech. These signals suggest CDK4/6 inhibition in CRC is being pursued along two distinct mechanistic tracks simultaneously.

Biomarker stratification is expanding beyond MSI/KRAS. USC’s genomic polymorphism patents document SNPs in VEGF and VEGFR2 (KDR) as predictors of bevacizumab-based therapy response. Merck Patent GmbH’s active portfolio motivates biomarker discovery beyond KRAS — including EREG and AREG expression — for cetuximab efficacy prediction. Hiloprobe AB (Sweden) holds an extensive active multi-jurisdictional portfolio on SLC35D3/POSTN/KLK6/MUC2 biomarkers for CRC prognosis and metastasis prediction. And Gil Medical Center’s 2023 US patent introduces obesity-related immune signature as a novel patient stratification layer. The cumulative picture is of a field moving rapidly towards multi-biomarker, multi-pathway patient selection — a trend that creates both companion diagnostic IP opportunities and clinical trial design complexity.